Abstract: Lymphovascular invasion (LVI) of testicular germ cell tumors (GCT) is an important stage-determining variable in the evaluation of radical orchiectomy specimens. ERG endothelial cell expression, as detected by immunohistochemistry (IHC), robustly highlights lymphovascular spaces, and thus, we sought to assess the utility of ERG IHC for evaluation of GCT LVI. Hematoxylin and eosin (H&E) slides from a retrospective cohort of 25 GCT radical orchiectomy specimens (emanating from a parent cohort of 159 radical orchiectomy GCT cases identified between 2003 and 2013) were reviewed, and sections with foci of positive or equivocal LVI were identified. ERG IHC was performed on sections off the surface of corresponding paraffin tissue blocks. All foci were then rescored as positive, equivocal, or negative for LVI based on ERG endothelial cell expression. Twenty-three and 13 foci were positive or equivocal for LVI by H&E staining, respectively. Among the H&E positive LVI foci, 20 (87%) were ERG IHC positive, whereas of the H&E equivocal LVI foci, 5 (38%) were ERG IHC positive, 3 (23%) were ERG IHC negative, and 2 (15%) were ERG IHC equivocal; all other foci were lost for evaluation. Overall, ERG IHC helped resolve the LVI status of 61% of foci deemed equivocal for LVI by H&E staining only. Although ERG IHC is useful in confirming definitive LVI status in a subset of GCT cases, the overall clinical impact of ERG IHC is limited for H&E equivocal LVI foci in this specific retrospective patient cohort. Overall, in carefully selected clinical scenarios, these data suggest a supportive role for ERG IHC in evaluation of GCT LVI in radical orchiectomy specimens. T esticular cancer accounts for ∼1% of all malignant tumors in men but is the most common neoplasm in men aged 15 to 45 years. 1-3 The vast majority ( > 95%) of testicular cancers are germ cell tumors (GCT), a diverse histopathologic group of related neoplasms that include seminoma, embryonal carcinoma, yolk sac tumor, choriocarcinoma, and teratoma. These GCT subtypes can be found either as pure tumors or admixed in varying quantities, and clinically, testicular GCT are separated into 2 main groups: pure seminoma and nonseminomatous GCT (NSGCT). 4 Lymphovascular invasion (LVI) is a pathologic "T" stage-defining variable for testicular GCT. 2 Sandeman and Matthews 5 first demonstrated that the presence of LVI in otherwise organ-confined tumors helped define a subset of patients with worse overall prognosis. Multiple follow-up studies in large cohorts of testicular GCT patients without clinical evidence of metastatic disease at presentation have confirmed that the presence of LVI in the radical orchiectomy specimen is an important prognostic factor for both occult metastasis and relapse after a negative retroperitoneal lymph node dissection (RPLND). [6] [7] [8] [9] [10] [11] In radical orchiectomy specimens for testicular GCT, the presence or absence of LVI can usually be determined by adequate sampling and routine hematoxylin and eosin (H&E) staining, however, some cases present challenging diagnostic dilemmas. 12 How LVI status is determined in these equivocal cases is not currently standardized, and there is no gold standard for LVI determination. The recent growing armamentarium of ancillary techniques-most notably immunohistochemistry (IHC)-has spurred the development of novel methods for assessing LVI. Indeed, IHC for vascular and/or lymphatic endothelial cell markers, including CD31, CD34, and D2-40 (podoplanin), has been evaluated for the detection of LVI in melanoma, as well as breast, prostate, colon, gastric, and bladder cancer. [13] [14] [15] [16] [17] [18] [19] [20] Despite the central importance of LVI status in its pathologic staging, no extensive studies regarding the use of IHC for classifying LVI in primary testicular GCT have been reported in the published literature. ERG, a member of the ETS family of transcription factors, has recently been implicated in prostate cancer pathogenesis. 21, 22 ERG is also expressed by normal vascular and lymphatic endothelium, 23 where it plays an important role in vascular development. 24 ERG IHC has been evaluated for the assessment of LVI in colon cancer. 25 In that study, after a group consensus session, ERG IHC was found to increase LVI detection and
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MATERIALS AND METHODS
A comprehensive retrospective search of the Michigan Medicine pathology records database was performed to identify all radical orchiectomy specimens between January 2002 and May 2013. H&E slides for all cases reporting positive or equivocal LVI were reviewed by 3 study pathologists (A.M.U., J.B.M., and R.M.), and sections with H&E positive or equivocal LVI foci were identified for further investigation. On the basis of current clinical practice standards, intravascular tumor cell aggregates with a smooth contour, attachment to endothelium, and admixed fibrin were designated as H&E positive for LVI 12 ; for the purposes of this study, foci with some, but not all, of these features were designated as H&E equivocal for LVI.
For all H&E positive or equivocal foci, sections off the surface of corresponding paraffin tissue blocks were obtained (ie, "off the top" sections), and ERG IHC (EPR3864; pre-dilute; Ventana Medical Systems, Tucson, AZ) was performed using a BenchMark ULTRA automated stainer and the ultraView Universal DAB Detection Kit (Ventana Medical Systems). All foci were then rescored as positive, equivocal, or negative for LVI based on ERG endothelial cell expression by three study pathologists (A.M.U., J.B.M., and R.M.). Foci which demonstrated all or some of the features for LVI (see above) and exhibited a complete peripheral layer of endothelial cells (as visualized by nuclear ERG protein expression) were designated ERG IHC positive for LVI, whereas foci with an incomplete peripheral endothelial cell layer or without endothelial cells entirely were designated ERG IHC equivocal and negative for LVI, respectively. All study investigators were blinded to specific clinical information (ie, the presence or absence of clinical or pathologic metastasis, etc.) until after scoring ERG LVI foci, at which point additional clinicopathologic details for each case were obtained from the electronic medical record. Clinical staging for all patients at the time of diagnosis was based on the American Joint Committee on Cancer (AJCC) clinical staging system. 2 
RESULTS

Clinicopathologic Features of a Retrospective GCT Cohort
Overall, 159 radical orchiectomy GCT cases were identified in the study period. Among these, 40 (25%) reported positive or equivocal LVI, whereas the other 119 (75%) were negative for LVI. Upon retrospective evaluation of the H&E slides for cases reporting positive or equivocal LVI, 25 out of 40 (63%) with H&E positive or equivocal LVI foci were identified and available for ERG IHC (Table 1) . For the remaining 15 cases, either the slides and/or blocks were not immediately available for inclusion in the study or the case was deemed negative for LVI (ie, no positive or equivocal LVI foci were identified on retrospective review); the most common reason for discordance between reported and retrospectively reviewed LVI status was so-called "pseudolymphovascular invasion"-a well-known diagnostic challenge in testicular GCT. 12 Patient age at the time of radical orchiectomy ranged from 16 to 65 years (median = 25 y), and there were 10 right testicular and 15 left testicular GCT. The maximum tumor dimension ranged in size from 1.2 to 8.0 cm (median = 3.2 cm), and there were 5 pure seminomas and 20 NSGCT. Assignment of AJCC pathologic "T" stage classification yielded 1 "pT1" tumor, 21 "pT2" tumors, and 3 "pT3" tumors. Among the 21 "pT2" tumors, only 2 (10%) demonstrated invasion of the tunica vaginalis-the other "pT2" stage-defining pathologic feature besides LVI. 2 Eighteen patients out of 25 have had clinical and/or pathologic evidence of metastasis either at the time of diagnosis or during subsequent follow-up, whereas 7 patients have had no evidence of metastatic spread (including 2 who underwent primary RPLND). One patient had persistently elevated serum tumor markers only (ie, no definite metastatic site could be determined based on radiographic imaging). At last follow-up, all but 1 of the patients were alive and clinically free of disease, with a follow-up range of 1 to 114 months (median = 25 mo).
Impact of ERG IHC on LVI Assessment of Individual LVI Foci
First, we decided to determine the impact of ERG IHC on LVI assessment of individual LVI foci in this GCT cohort. From the 25 cases with H&E positive or equivocal LVI foci, retrospective evaluation of the H&E slides revealed 36 H&E positive or equivocal LVI foci: 23 H&E positive LVI foci and 13 H&E equivocal LVI foci. Among the 23 H&E positive LVI foci, 20 (87%) were designated as positive for LVI based upon ERG IHC, 3 were lost for evaluation, and none were ERG IHC equivocal or negative ( Fig. 1 and Table 2 ). The GCT component identified in these H&E positive LVI foci were comprised of embryonal carcinoma (17 foci), seminoma (2 foci), yolk sac tumor (2 foci), and choriocarcinoma (2 foci), which corresponded to the dominant GCT component (in terms of percentage of volume of the entire tumor) in all cases except the 2 foci of yolk sac tumor; in these 2 cases, the dominant GCT component was embryonal carcinoma. Among the 13 H&E equivocal LVI foci, 5 (39%) were designated as positive based on ERG IHC, 3 (23%) were ERG IHC negative, 2 (15%) were ERG IHC equivocal, and 3 (23%) were lost upon sectioning for evaluation (Figs. 2, 3 ; Table 2 ; see Materials and Methods section for details). The GCT component present in these equivocal H&E LVI foci included embryonal carcinoma (6), seminoma (5), and choriocarcinoma (2), which again corresponded to the dominant GCT subtype in all cases except 1 focus of embryonal carcinoma; in that case, the dominant GCT component was teratoma. 
Impact of ERG IHC on LVI Assessment of Individual Cases
After determining the utility of ERG IHC for LVI assessment of individual LVI foci, we next sought to establish whether ERG IHC had an impact on the overall LVI status of individual cases, which, in turn, could impact pathologic and clinical classification. All told, 19 cases were positive for LVI based on H&E and/or ERG IHC evaluation, whereas the remaining 6 were either negative or equivocal for LVI. Among the 19 LVI positive cases, all were originally classified as either "pT2" or "pT3," and therefore, ERG IHC would not have affected the pathologic staging of these cases. In contrast, of the 6 LVI negative or equivocal cases, 1 was originally classified as "pT1" and the other 5 as "pT2"; none of these tumors demonstrated tunica vaginalis invasion, and therefore, the presence (or absence) of LVI in cases was pathologic "T" stage defining. On the basis of our retrospective analysis, ERG IHC would have confirmed the absence of LVI in 2 cases, only 1 of which was originally classified as "pT2." Therefore, ERG IHC would have had a positive albeit limited impact on the overall pathologic staging on this cohort.
Overall, 16 out of 25 cases had at least 1 H&E positive LVI focus-15 (94%) of which also had at least 1 ERG IHC positive LVI focus. Fifteen (88%) of these H&E positive foci were also ERG LVI positive, whereas the other 2 were lost for evaluation upon sectioning. Both H&E equivocal foci were positive for LVI by ERG IHC. The 4 clinical stage I tumors corresponded to 6 H&E positive or equivocal LVI foci (all involving embryonal carcinoma): 5 H&E positive LVI foci and 1 H&E equivocal LVI focus. Four of these foci (from 3 total cases) were ERG IHC positive, whereas the other 2 (including the H&E equivocal focus) were lost for evaluation upon sectioning. Neither of the clinical stage IB tumors had evidence of tunica vaginalis or spermatic cord invasion (ie, LVI was pathologic "T" stage defining). Three of these clinical stage I patients ultimately underwent RPLND, which confirmed GCT metastasis in retroperitoneal lymph nodes; the fourth patient-who had persistently elevated serum tumor markers only-was treated with chemotherapy, after which his serum tumor markers normalized.
Among the Four cases (out of 9 without at least 1 H&E positive LVI focus) were unable to be definitively designated as either positive or negative for LVI based on H&E and ERG IHC evaluation. One clinical stage IIA tumor had only a single H&E equivocal focus (involving choriocarcinoma), which was equivocal for LVI based on ERG IHC. Three clinical stage I tumors corresponded to 3 H&E equivocal LVI foci (all involving embryonal carcinoma); 1 focus was ERG IHC equivocal, and the other 2 foci were lost for evaluation. None of the clinical stage I tumors had evidence of tunica vaginalis or spermatic cord invasion (ie, LVI was stage defining), and at last follow-up (range, 9 to 89 mo), none of these clinical stage I patients had developed clinical or pathologic evidence of GCT metastasis. Chorio indicates choriocarcinoma; EC, embryonal carcinoma; equiv, equivocal; GCT, germ cell tumors; H&E, hematoxylin and eosin; IHC, immunohistochemistry; LVI, lymphovascular invasion; neg, negative; pos, positive; sem, seminoma; YS, yolk sac tumor.
DISCUSSION
For surgical pathologists, our data suggest at least 3 possible scenarios for which ERG IHC may be useful: confirmation of H&E positive LVI foci (group 1); converting H&E equivocal LVI foci to positive for LVI (group 2); and converting H&E equivocal LVI foci to negative for LVI (group 3). For group 1, our data indicate a high rate of concordance between H&E and ERG IHC, as nearly 90% of H&E positive LVI foci were also ERG IHC positive ( Fig. 1 and Table 2 ). Only 3 H&E positive LVI foci were not confirmed by ERG IHC, and in all of these instances, the positive focus was lost for evaluation upon sectioning for IHC (importantly, no H&E positive LVI foci were ERG IHC equivocal or negative). For groups 2 and 3, our data suggest that more than half of H&E equivocal LVI foci may be resolved by ERG IHC (Figs. 2, 3 and Table 2 ). Indeed, of the H&E equivocal LVI foci available for ERG IHC evaluation (ie, not lost for evaluation upon sectioning), 8 (80%) were ultimately able to be designated as either positive or negative for LVI by ERG IHC. Therefore, we propose a possible algorithmic approach to utilizing ERG IHC for evaluation of LVI in testicular GCT, whereby ERG IHC is used predominantly for the classification of H&E equivocal LVI foci and only sparingly for confirmation in H&E positive LVI cases, as deemed clinically appropriate or necessary (Fig. 4) .
Although our data suggest possible utility of ERG IHC for confirming or clarifying LVI status of individual LVI foci in testicular GCT at the time of radical orchiectomy, the potential patient-level impact is not as clear and needs to be resolved by additional studies. For treating clinicians, the presence or absence of LVI in testicular GCT at the time of radical orchiectomy is most important in the context of organ-confined tumors without clinical evidence of metastasis by staging radiographs or serum tumor markers. 2, [5] [6] [7] [8] [9] [10] [11] For these patients, LVI-in addition to other clinicopathologic variables, such as the overall percentage of embryonal carcinoma, absence of teratoma, rete testis invasion, etc.-helps determine the overall risk of occult metastasis and/or recurrence, which may impact the treatment options offered (ie, primary RPLND or chemotherapy). Indeed, presence or absence of LVI has been demonstrated to be a very powerful predictor of relapse for clinical stage I NSGCT patients. 11, 27 Although our study was not specifically designed to evaluate the prognostic value of ERG IHC for LVI evaluation in clinical stages IA or IB testicular GCT tumors, there were 9 such cases in our cohort: 2 with at least 1 H&E positive LVI focus; and, 7 with only H&E equivocal foci. For both of the tumors with at least 1 H&E positive LVI focus, ERG IHC confirmed the presence of LVI, and these patients subsequently developed pathologic evidence of GCT metastasis. Among the 7 tumors with only H&E equivocal foci, 2 (29%) were LVI positive by ERG IHC, 2 (29%) were LVI negative by ERG IHC, 1 (13%) was LVI equivocal by ERG IHC, and 2 (29%) were lost for evaluation, and at last follow-up, none of these patients have developed clinical or pathologic evidence of GCT metastasis. This is a particularly important finding given the relatively low frequency, in our cohort, of H&E positive LVI foci in patients without clinical evidence of metastasis at diagnosis compared with patients with evidence of metastasis (22% vs. 88%, respectively). Therefore, surgical pathologists should tread carefully in cases where only H&E equivocal foci are present, as these tumors in our current retrospective cohort of GCT did not show subsequent clinical or pathologic evidence of GCT metastasis in the limited follow-up time available for these patients. These data suggest that the presence of LVI in such cases should only be reported when unequivocally confirmed by ERG IHC. Further studies are warranted to investigate such specific clinical scenarios.
In this study, we investigated the utility of ERG IHC for evaluation of GCT LVI in radical orchiectomy specimens, however, there are a number of other options available for surgical pathologists to address this issue, including submitting additional tissue for histopathologic review and obtaining "off the top" H&E stained sections. Obviously, in a retrospective study, submitting additional tissue for histopathologic review is not feasible, but even in the prospective setting, there is a practical limit to this approach (ie, eventually all possible useful tissue will be expended). It seems reasonable that decisions regarding additionally submitted tissue be handled on a case-by-case basis, at the signing pathologist's discretion. Our study was not specifically designed to compare "off the top" ERG IHC and H&E stained sections for GCT LVI evaluation, but at least in some instances, our data seem to indicate that an additional "off the top" H&E stained section alone may help resolve LVI status of H&E equivocal LVI foci (Figs. 2C-F) . Of course, even in these cases, ERG IHC may provide an extra layer of confirmation of LVI status. Finally, other IHC markers, including CD31, CD34, and D2-40, have been evaluated for LVI assessment in other tumors. [13] [14] [15] [16] [17] [18] [19] [20] In contrast to ERG, all of these markers have non-nuclear staining patterns, which may be less helpful for LVI evaluation. To date, only 1 published report with colon cancer cases has compared these markers (CD31, D2-40, and ERG) for LVI assessment. 25 In that study, endothelial cell discrimination by nuclear ERG IHC was preferred to nonnuclear CD31 and D2-40 IHC, and ERG IHC increased LVI detection and decreased interobserver variability among pathologists, after a group consensus session. Finally, given the known strong, robust expression of D2-40 by seminomas, [28] [29] [30] any utility of D2-40 IHC for GCT LVI would likely be limited to foci with nonseminomatous components. In any event, the superiority of ERG IHC for evaluation of GCT LVI, as compared with other available LVI IHC markers, was not addressed here and remains an area of possible future exploration.
